If there were a licensing/buyout in the works, I w
Post# of 148181
I would wager an offer of around $35-$50 on good results. Sure no recurring revenues atm, but with a buttload of leronlimab on tap and CV19/HIV revenues expected to start this year, investors should consider this a growth company and price accordingly.